Bacil Pharma Ltd Financials
Company Logo

Bacil Pharma Ltd Financial Statement

Bacil Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue1.00
Operating Expense0.11
Net Profit0.67
Net Profit Margin67.00
Earning Per Share0.48
EBIDTA0.89
Effective Tax Rate24.72

Bacil Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue AnnualTBA
Operating Expenses Annual0.25
Operating Profit Annual0.41
Interest AnnualTBA
Depreciation0.00
Net Profit Annual0.40
Tax Annual0.00

Bacil Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.04
Cash Flow from Operations0.40
Cash Flow from Investing0.34
Cash Flow from Financing2.08
Cash Flow at the End2.86

Bacil Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)-0.98
Return On Networth /Employed (%)-1.04
Return On Assets (%)TBA
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)TBA

Bacil Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets AnnualTBA
Total Current Assets Annual2.91
Non Current Assets Annual22.69
Total Shareholders Funds Annual25.43
Total Assets Annual25.60

Bacil Pharma Ltd Earning Calls

No Data Availabe

FAQS on Bacil Pharma Ltd Financials

As of Sep 28, 2025, Bacil Pharma Ltd has a market capitalization of 60.99 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Bacil Pharma Ltd is with a debt-to-equity ratio of 0.01.

In FY 2024 , Bacil Pharma Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.

Bacil Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 1.5% and NaN% annually, respectively..

Bacil Pharma Ltd's current PE ratio is 152.47.

Bacil Pharma Ltd's ROCE averaged -4.0% from the FY ending March 2023 to 2025, with a median of -4.5%. It peaked at 1.6% in March 2025, reflecting strong capital efficiency over the period..

Bacil Pharma Ltd's latest EBIT is Rs. 0.41 Cr, surpassing the average EBIT of Rs. 0.08 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions